MET and breast carcinoma: Eventually, we compared the metastatic capacity of CTC populations isolated from two luminal breast cancer patients with different MET+CD47+ cellular contents, using our previously established CTC-xenograft assay, in order to directly evaluate the functional relevance of MET-CD47 co-expression in vivo.